Expression of thymidine phosphorylase and cyclooxygenase-2 in melanoma

Melanoma Research

Volumn 23, Issue 2, 2013, Pages 96-101

  Minisini, Alessandro M ^a   Pascoletti, Gaetano ^a   Intersimone, Donatella ^a   Poletto, Elena ^a   Driol, Pamela ^a   Spizzo, Riccardo ^b   Scott, Cathryn A ^a   Puglisi, Fabio ^a   Fasola, Gianpiero ^a   Di Loreto, Carla ^a  

^a UNIVERSITY HOSPITAL OF UDINE   (Italy)

^b Division of Experimental Oncology 2   (Italy)

Author keywords

cyclooxygenase 2; melanoma; prognostic factors; thymidine phosphorylase

Indexed keywords

CYCLOOXYGENASE 2; MESSENGER RNA; THYMIDINE PHOSPHORYLASE;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER PROGNOSIS; CUTANEOUS MELANOMA; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; MALE; MITOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

EID: 84874947281     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0b013e32835e7734     Document Type: Article

References (28)

1. Dummer R, Hauschild A, Guggenheim M, Jost L, Pentheroudakis G. ESMO Guidelines Working Group. Melanoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21 (Supp 5): v197-v197.
2. Toi M, Atiqur Rahman M, Bando H, Chow LW. Thymidine phosphorylase (platelet-derived endothelial-cell growth factor) in cancer biology and treatment. Lancet Oncol 2005; 6:158-166.
3. Takebayashi Y, Akiyama S, Akiba S, Yamada K, Miyadera K, Sumizawa T, et al. Clinicopathologic and prognostic significance of an human angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma. J Natl Cancer Inst 1996; 19:709-716.
4. Arima J, Imazono Y, Takebayashi Y, Nishiyama K, Shirahama T, Akiba S, et al. Expression of thymidine phosphorylase as an indicator of poor prognosis for patients with transitional cell carcinoma of the bladder. Cancer 2000; 88:1131-1138.
5. Hata K, Takebayashi Y, Iida K, Fujiwaki R, Fukumoto M, Miyazaki K. Expression of thymidine phosphorylase in human cervical cancer. Anticancer Res 1999; 19:709-716.
6. Takebayashi Y, Miyadera K, Akiyama S, Hokita S, Yamada K, Akiba S, et al. Expression of thymidine phosphorylase in human gastric carcinoma. Jpn J Cancer Res 1996; 87:288-295.
7. Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B, Kwong E, et al. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996; 87:803-809.
8. Tucker ON, Dannenberg AJ, Yang EK, Zhang F, Teng L, Daly JM, et al. Cyclooxygenase-2 expression is upregulated in human pancreatic cancer. Cancer Res 1999; 59:987-990.
9. Koga H, Sakisaka S, Ohishi M, Kawaguchi T, Taniguchi E, Sasatomi K, et al. Expression of cyclooxygenase-2 in human hepatocellular carcinoma: relevance to tumor differentiation. Hepatology 1999; 29:688-696.
10. Wolff H, Saukkonen K, Anttila S, Karjalainen A, Vainio H, Ristimä ki A, et al. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res 1998; 58:4997-5001.
11. Chan G, Boyle JO, Yang EK, Zhang F, Sacks PG, Shah JP, et al. Cyclooxygenase-2 expression is upregulated in squamous cell carcinoma of the head and neck. Cancer Res 1999; 59:991-994.
12. Denkert C, Kö bel M, Berger S, Siegert A, Leclere A, Trefzer U, et al. Expression of cyclooxygenase 2 in human malignant melanoma. Cancer Res 2001; 61:303-308.
13. Vogt T, McClelland M, Jung B, Popova S, Bogenrieder T, Becker B, et al. Progression and NSAID-induced apoptosis in malignant melanomas are independent of cyclooxygenase II. Melanoma Res 2001; 11:587-599.
14. Johansson CC, Egyhá zi S, Masucci G, Harlin H, Mougiakakos D, Poschke I, et al. Prognostic significance of tumor iNOS and COX-2 in stage III malignant cutaneous melanoma. Cancer Immunol Immunother 2009; 58:1085-1094.
15. Becker MR, Siegelin MD, Rompel R, Enk AH, Gaiser T. COX-2 expression in malignant melanoma: a novel prognostic marker? Melanoma Res 2009; 19:8-16.
16. Tsuda H, Akiyama F, Kurosumi M, Sakamoto G. Reproducible immunohistochemical criteria based on multiple raters' judgments for expression of thymidine phosphorylase in breast cancer tissue. Breast Cancer Res Treat 2004; 86:215-223.
17. Humar B, Giovanoli O, Wolf A, Attenhofer M, Bendik I, Meier R, et al. Germline alterations in the cyclooxygenase-2 gene are not associated with the development of extracolonic manifestations in a large Swiss familial adenomatous polyposis kindred. Int J Cancer 2000; 87:812-817.
18. Sales KJ, Katz AA, Davis M, Hinz S, Soeters RP, Hofmeyr MD, et al. Cyclooxygenase-2 expression and prostaglandin E(2) synthesis are upregulated in carcinomas of the cervix: a possible autocrine/paracrine regulation of neoplastic cell function via EP2/EP4 receptors. J Clin Endocrinol Metab 2001; 86:2243-2249.
19. Komuro H, Kaneko S, Kaneko M, Nakanishi Y. Expression of angiogenic factors and tumor progression in human neuroblastoma. J Cancer Res Clin Oncol 2001; 127:739-743.
20. Schmittgen TD, Lee EJ, Jiang J. High-throughput real-time PCR. Methods Mol Biol 2008; 429:89-98.
21. Puglisi F, Andreetta C, Valent F, Minisini AM, Rijavec E, Russo S, et al. Anthracyclines and taxanes induce the upregulation of thymidine phosphorylase in breast cancer cells. Anticancer Drugs 2007; 18: 883-888.
22. Fukushima M, Okabe H, Takechi T, Ichikawa W, Hirayama R. Induction of thymidine phosphorylase by interferon and taxanes occurs only in human cancer cells with low thymidine phosphorylase activity. Cancer Lett 2002; 187:103-110.
23. Giatromanolaki A, Sivridis E, Kouskoukis C, Gatter KC, Harris AL, Koukourakis MI. Hypoxia-inducible factors 1alpha and 2alpha are related to vascular endothelial growth factor expression and a poorer prognosis in nodular malignant melanomas of the skin. Melanoma Res 2003; 13: 493-501.
24. Kuzbicki L, Lange D, Chwirot BW. Cyclooxygenase-2 immunohistochemistry in human melanoma: differences between results obtained with different antibodies. Melanoma Res 2009; 19:294-300.
25. Minami S, Lum CA, Kitagawa KM, Namiki TS. Immunohistochemical expression of cyclooxygenage-2 in melanocytic skin lesions. Int J Dermatol 2011; 50:24-29.
26. Bhatt RS, Merchan J, Parker R,Wu HK, Zhang L, Seery V, et al. A phase 2 pilot trial of low-dose, continuous infusion, or 'metronomic' paclitaxel and oral celecoxib in patients with metastatic melanoma. Cancer 2010; 116:1751-1756.
27. Reichle A, Bross K, Vogt T, Bataille F,Wild P, Berando A, et al. Pioglitazone and rofecoxib combined with angiostatically scheduled trofosfamide in the treatment of far-advanced melanoma and soft tissue sarcoma. Cancer 2004; 101:2247-2256.
28. Spieth K, Kaufmann R, Gille J. Metronomic oral low-dose treosulfan chemotherapy combined with cyclooxygenase-2 inhibitor in pretreated advanced melanoma: a pilot study. Cancer Chemother Pharmacol 2003; 52:377-382.